›
‹
- 1
- 2
- 3
- 4
- 5
Latest News
-
Executive Leadership Transition
After 14 years, Sue Kahn plans to step down. Read a letter from Sue and learn more about the position. Read More -
Passage Bio's First Patient Dosed
The first patient has been dosed in Imagine-1 study of PBGM01 gene therapy for infantile GM1 gangliosidosis. Read More -
Lysogene Clinical Trial
FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1. Read More
- 1
- 2
- 3
- 4
›
‹
NTSAD leads the worldwide fight to treat and cure Tay-Sachs, Canavan, GM1, and Sandhoff diseases by driving research, forging collaboration, and fostering community. Supporting families is the center of everything we do.
- Default
- Title
- Date
- Random
